Moderna Cuts R&D by $1.1B, Focus on Key Approvals
Moderna shares dip as R&D spending reduces, focusing on FDA approval for 10 key products including RSV and cancer treatments.
- Latest
- Trending
Moderna shares dip as R&D spending reduces, focusing on FDA approval for 10 key products including RSV and cancer treatments.
European companies express growing caution about investing in China due to market complexities and geopolitical tensions.
RTX explores alternatives to China suppliers amid labor shortages and geopolitical risks in the aerospace industry.
Klarna eyes US share sale before IPO, valued at $20B, backed by Sequoia and Softbank.
Hyperspace closes its Solana NFT marketplace amid ongoing challenges in the digital asset market.
US small business startup applications surge in 2024, fueled by improving sentiment and eased inflation, says Treasury report.
AI is transforming medical research, but technological illiteracy poses significant hurdles in the health sector.
Super Micro Computer and AMD are poised for growth in AI. Discover why these stocks could be great investment opportunities.
S&P 500 dips 0.9% with tech slump, Moderna drops 6.5% post-vaccine approval, market awaits Fed's Powell.
Trailrunner enhances broadband in rural Maine using Tarana Wireless, impacting 8 counties with high-speed, reliable internet.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.